Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q3 2024 · 10-Q
Revenue$3.78M$3.78M+203.3% vs Q3 2023 Net Income-$3.03M-$3.03MN/M vs Q3 2023 EPS Diluted-$0.02-$0.02N/M vs Q3 2023 Operating Income-$3,840,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$5,899,000N/M Margins · derivedOperating margin-101.6%+436.5 pt vs Q3 2023
Net margin-80.3%+490.3 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 14, 2024 · 45 d after period end